ID   MET_HUMAN               Reviewed;        1390 AA.
AC   P08581; O60366; Q12875; Q9UDX7; Q9UPL8;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   07-JUL-2009, sequence version 4.
DT   02-NOV-2010, entry version 154.
DE   RecName: Full=Hepatocyte growth factor receptor;
DE            Short=HGF receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=HGF/SF receptor;
DE   AltName: Full=Proto-oncogene c-Met;
DE   AltName: Full=Scatter factor receptor;
DE            Short=SF receptor;
DE   AltName: Full=Tyrosine-protein kinase Met;
DE   Flags: Precursor;
GN   Name=MET;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   MEDLINE=87317655; PubMed=2819873; DOI=10.1073/pnas.84.18.6379;
RA   Park M., Dean M., Kaul K., Braun M.J., Gonda M.A., Vande Woude G.;
RT   "Sequence of MET protooncogene cDNA has features characteristic of the
RT   tyrosine kinase family of growth-factor receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6379-6383(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Giordano S.;
RL   Submitted (NOV-1990) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22737999; PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1010-1390.
RX   MEDLINE=88143699; PubMed=3325883;
RA   Chan A.M.-L., King H.W.S., Tempest P.R., Deakin E.A., Cooper C.S.,
RA   Brookes P.;
RT   "Primary structure of the met protein tyrosine kinase domain.";
RL   Oncogene 1:229-233(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1206-1264.
RX   MEDLINE=94067791; PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1267-1390.
RX   MEDLINE=86065462; PubMed=4069211; DOI=10.1038/318385a0;
RA   Dean M., Park M., le Beau M.M., Robins T.S., Diaz M.O., Rowley J.D.,
RA   Blair D.G., Vande Woude G.F.;
RT   "The human met oncogene is related to the tyrosine kinase oncogenes.";
RL   Nature 318:385-388(1985).
RN   [7]
RP   FUNCTION.
RX   MEDLINE=91118019; PubMed=1846706; DOI=10.1126/science.1846706;
RA   Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M.-L., Kmiecik T.E.,
RA   Vande Woude G.F., Aaronson S.A.;
RT   "Identification of the hepatocyte growth factor receptor as the c-met
RT   proto-oncogene product.";
RL   Science 251:802-804(1991).
RN   [8]
RP   PHOSPHORYLATION AT TYR-1235, AND ATP-BINDING SITE LYS-1110.
RX   MEDLINE=92011756; PubMed=1655790;
RA   Ferracini R., Longati P., Naldini L., Vigna E., Comoglio P.M.;
RT   "Identification of the major autophosphorylation site of the
RT   Met/hepatocyte growth factor receptor tyrosine kinase.";
RL   J. Biol. Chem. 266:19558-19564(1991).
RN   [9]
RP   INTERACTION WITH GRB10.
RX   PubMed=10454568;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [10]
RP   INTERACTION WITH RANBP9.
RX   PubMed=12147692; DOI=10.1074/jbc.M205111200;
RA   Wang D., Li Z., Messing E.M., Wu G.;
RT   "Activation of Ras/Erk pathway by a novel MET-interacting protein
RT   RanBPM.";
RL   J. Biol. Chem. 277:36216-36222(2002).
RN   [11]
RP   INTERACTION WITH PLXNB1.
RX   MEDLINE=22194792; PubMed=12198496; DOI=10.1038/ncb843;
RA   Giordano S., Corso S., Conrotto P., Artigiani S., Gilestro G.,
RA   Barberis D., Tamagnone L., Comoglio P.M.;
RT   "The semaphorin 4D receptor controls invasive growth by coupling with
RT   Met.";
RL   Nat. Cell Biol. 4:720-724(2002).
RN   [12]
RP   INTERACTION WITH RANBP9 AND RANBP10.
RX   PubMed=14684163; DOI=10.1016/j.bbrc.2003.11.124;
RA   Wang D., Li Z., Schoen S.R., Messing E.M., Wu G.;
RT   "A novel MET-interacting protein shares high sequence similarity with
RT   RanBPM, but fails to stimulate MET-induced Ras/Erk signaling.";
RL   Biochem. Biophys. Res. Commun. 313:320-326(2004).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH MUC20.
RX   PubMed=15314156; DOI=10.1128/MCB.24.17.7456-7468.2004;
RA   Higuchi T., Orita T., Katsuya K., Yamasaki Y., Akiyama K., Li H.,
RA   Yamamoto T., Saito Y., Nakamura M.;
RT   "MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras
RT   pathway by binding to a multifunctional docking site of met.";
RL   Mol. Cell. Biol. 24:7456-7468(2004).
RN   [14]
RP   PHOSPHORYLATION AT TYR-1356, AND INTERACTION WITH INPPL1.
RX   PubMed=15735664; DOI=10.1038/sj.onc.1208558;
RA   Koch A., Mancini A., El Bounkari O., Tamura T.;
RT   "The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-
RT   Met directly via tyrosine residue 1356 and involves hepatocyte growth
RT   factor (HGF)-induced lamellipodium formation, cell scattering and cell
RT   spreading.";
RL   Oncogene 24:3436-3447(2005).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1003; TYR-1230; TYR-1234
RP   AND TYR-1235, AND MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-977; SER-988; SER-990
RP   AND TYR-1003, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-966; THR-977; SER-988;
RP   SER-990; SER-997; SER-1000 AND TYR-1003, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-990; SER-997 AND
RP   SER-1000, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-202, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-106, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Hepatoma;
RX   PubMed=19196183; DOI=10.1021/pr800826u;
RA   Cao J., Shen C., Wang H., Shen H., Chen Y., Nie A., Yan G., Lu H.,
RA   Liu Y., Yang P.;
RT   "Identification of N-glycosylation sites on secreted proteins of human
RT   hepatocellular carcinoma cells with a complementary proteomics
RT   approach.";
RL   J. Proteome Res. 8:662-672(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1234, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-966; THR-977; SER-988;
RP   SER-990; SER-997; SER-1000; TYR-1003; TYR-1234 AND THR-1289, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1356-1359 IN COMPLEX WITH
RP   GRB2.
RX   MEDLINE=20519033; PubMed=11063574; DOI=10.1021/bi0012336;
RA   Schiering N., Casale E., Caccia P., Giordano P., Battistini C.;
RT   "Dimer formation through domain swapping in the crystal structure of
RT   the Grb2-SH2-Ac-pYVNV complex.";
RL   Biochemistry 39:13376-13382(2000).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1049-1360 IN COMPLEX WITH
RP   INHIBITOR.
RX   MEDLINE=22946179; PubMed=14559966; DOI=10.1073/pnas.1734128100;
RA   Schiering N., Knapp S., Marconi M., Flocco M.M., Cui J., Perego R.,
RA   Rusconi L., Cristiani C.;
RT   "Crystal structure of the tyrosine kinase domain of the hepatocyte
RT   growth factor receptor c-Met and its complex with the microbial
RT   alkaloid K-252a.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:12654-12659(2003).
RN   [25]
RP   VARIANTS HPRC THR-1131; LEU-1188; VAL-1195; ILE-1220; HIS-1228;
RP   ASN-1228; CYS-1230; HIS-1230 AND THR-1250, AND VARIANT VAL-320.
RX   MEDLINE=97285124; PubMed=9140397; DOI=10.1038/ng0597-68;
RA   Schmidt L., Duh F.-M., Chen F., Kishida T., Glenn G., Choyke P.,
RA   Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R.,
RA   Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C.,
RA   Zamarron A., Bernues M., Richard S., Lips C.J.M., Walther M.M.,
RA   Tsui L.-C., Geil L., Orcutt M.L., Stackhouse T., Lipan J., Slife L.,
RA   Brauch H., Decker J., Niehans G., Hughson M.D., Moch H., Storkel S.,
RA   Lerman M.I., Linehan W.M., Zbar B.;
RT   "Germline and somatic mutations in the tyrosine kinase domain of the
RT   MET proto-oncogene in papillary renal carcinomas.";
RL   Nat. Genet. 16:68-73(1997).
RN   [26]
RP   VARIANT HPRC ARG-1094, AND CHARACTERIZATION OF VARIANT HPRC ARG-1094.
RX   PubMed=9563489;
RA   Schmidt L., Junker K., Weirich G., Glenn G., Choyke P., Lubensky I.,
RA   Zhuang Z., Jeffers M., Vande Woude G., Neumann H., Walther M.,
RA   Linehan W.M., Zbar B.;
RT   "Two North American families with hereditary papillary renal carcinoma
RT   and identical novel mutations in the MET proto-oncogene.";
RL   Cancer Res. 58:1719-1722(1998).
RN   [27]
RP   VARIANTS HPRC ILE-1092; ARG-1094; ASP-1106; THR-1131; LEU-1188;
RP   ASP-1230; CYS-1230 AND THR-1250.
RX   PubMed=10433944;
RA   Lubensky I.A., Schmidt L., Zhuang Z., Weirich G., Pack S.,
RA   Zambrano N., Walther M.M., Choyke P., Linehan W.M., Zbar B.;
RT   "Hereditary and sporadic papillary renal carcinomas with c-met
RT   mutations share a distinct morphological phenotype.";
RL   Am. J. Pathol. 155:517-526(1999).
RN   [28]
RP   VARIANTS HCC ILE-1173; ARG-1244 AND ILE-1250.
RX   PubMed=9927037;
RA   Park W.S., Dong S.M., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., Kim B.J.,
RA   Bae J.H., Hong Y.K., Lee K.S., Lee S.H., Yoo N.J., Jang J.J., Pack S.,
RA   Zhuang Z., Schmidt L., Zbar B., Lee J.Y.;
RT   "Somatic mutations in the kinase domain of the Met/hepatocyte growth
RT   factor receptor gene in childhood hepatocellular carcinomas.";
RL   Cancer Res. 59:307-310(1999).
RN   [29]
RP   VARIANT HPRC ILE-1092, AND CHARACTERIZATION OF VARIANT HPRC ILE-1092.
RX   PubMed=10417759;
RX   DOI=10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6;
RA   Olivero M., Valente G., Bardelli A., Longati P., Ferrero N.,
RA   Cracco C., Terrone C., Rocca-Rossetti S., Comoglio P.M.,
RA   Di Renzo M.F.;
RT   "Novel mutation in the ATP-binding site of the MET oncogene tyrosine
RT   kinase in a HPRCC family.";
RL   Int. J. Cancer 82:640-643(1999).
RN   [30]
RP   VARIANTS HPRC ILE-1092; LEU-1094; TYR-1094; ASP-1106 AND ASP-1230, AND
RP   CHARACTERIZATION OF VARIANTS HPRC ILE-1092; LEU-1094; TYR-1094;
RP   ASP-1106 AND ASP-1230.
RX   PubMed=10327054; DOI=10.1038/sj.onc.1202547;
RA   Schmidt L., Junker K., Nakaigawa N., Kinjerski T., Weirich G.,
RA   Miller M., Lubensky I., Neumann H.P.H., Brauch H., Decker J.,
RA   Vocke C., Brown J.A., Jenkins R., Richard S., Bergerheim U.,
RA   Gerrard B., Dean M., Linehan W.M., Zbar B.;
RT   "Novel mutations of the MET proto-oncogene in papillary renal
RT   carcinomas.";
RL   Oncogene 18:2343-2350(1999).
RN   [31]
RP   VARIANT GASTRIC CANCER SER-991, VARIANT ILE-992, CHARACTERIZATION OF
RP   VARIANT GASTRIC CANCER SER-991, AND CHARACTERIZATION OF VARIANT
RP   ILE-992.
RX   PubMed=11042681; DOI=10.1038/sj.onc.1203874;
RA   Lee J.-H., Han S.-U., Cho H., Jennings B., Gerrard B., Dean M.,
RA   Schmidt L., Zbar B., Vande Woude G.F.V.;
RT   "A novel germ line juxtamembrane Met mutation in human gastric
RT   cancer.";
RL   Oncogene 19:4947-4953(2000).
RN   [32]
RP   VARIANT GASTRIC CANCER LEU-773.
RX   PubMed=12920089; DOI=10.1136/jmg.40.8.e97;
RA   Kim I.-J., Park J.-H., Kang H.C., Shin Y., Lim S.-B., Ku J.-L.,
RA   Yang H.-K., Lee K.U., Park J.-G.;
RT   "A novel germline mutation in the MET extracellular domain in a Korean
RT   patient with the diffuse type of familial gastric cancer.";
RL   J. Med. Genet. 40:E97-E97(2003).
RN   [33]
RP   INTERACTION WITH SPSB1; SPSB2; SPSB3 AND SPSB4.
RX   PubMed=15713673; DOI=10.1074/jbc.M413897200;
RA   Wang D., Li Z., Messing E.M., Wu G.;
RT   "The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with
RT   MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum
RT   response element pathway.";
RL   J. Biol. Chem. 280:16393-16401(2005).
RN   [34]
RP   POSSIBLE INVOLVEMENT IN SUSCEPTIBILITY TO AUTS9, AND VARIANTS CYS-970
RP   AND ILE-992.
RX   PubMed=17053076; DOI=10.1073/pnas.0605296103;
RA   Campbell D.B., Sutcliffe J.S., Ebert P.J., Militerni R., Bravaccio C.,
RA   Trillo S., Elia M., Schneider C., Melmed R., Sacco R., Persico A.M.,
RA   Levitt P.;
RT   "A genetic variant that disrupts MET transcription is associated with
RT   autism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:16834-16839(2006).
RN   [35]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-143; LEU-156; ASP-168; SER-375;
RP   CYS-970 AND ILE-992.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor for hepatocyte growth factor and scatter
CC       factor. Has a tyrosine-protein kinase activity. Functions in cell
CC       proliferation, scattering, morphogenesis and survival.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Heterodimer formed of an alpha chain (50 kDa) and a beta
CC       chain (145 kDa) which are disulfide linked. Binds PLXNB1 and GRB2.
CC       Interacts with SPSB1, SPSB2 and SPSB4 (By similarity). Interacts
CC       with INPP5D/SHIP1. When phosphorylated at Tyr-1356, interacts with
CC       INPPL1/SHIP2. Interacts with RANBP9 and RANBP10, as well as SPSB1,
CC       SPSB2, SPSB3 and SPSB4. SPSB1 binding occurs in the presence and
CC       in the absence of HGF, however HGF treatment has a positive effect
CC       on this interaction. Interacts with MUC20; prevents interaction
CC       with GRB2 and suppresses hepatocyte growth factor-induced cell
CC       proliferation. Interacts with GRB10.
CC   -!- INTERACTION:
CC       P14210:HGF; NbExp=2; IntAct=EBI-1039152, EBI-1039104;
CC       P25147:inlB (xeno); NbExp=3; IntAct=EBI-1039152, EBI-1379295;
CC       O43157:PLXNB1; NbExp=6; IntAct=EBI-1039152, EBI-1111488;
CC       O15031:PLXNB2; NbExp=2; IntAct=EBI-1039152, EBI-722004;
CC       Q9ULL4:PLXNB3; NbExp=2; IntAct=EBI-1039152, EBI-311073;
CC       Q05209:PTPN12; NbExp=1; IntAct=EBI-1039152, EBI-2266035;
CC       P26045:PTPN3; NbExp=1; IntAct=EBI-1039152, EBI-1047946;
CC       P08575:PTPRC; NbExp=1; IntAct=EBI-1039152, EBI-1341;
CC       P23470:PTPRG; NbExp=1; IntAct=EBI-1039152, EBI-2258115;
CC       Q12913:PTPRJ; NbExp=1; IntAct=EBI-1039152, EBI-2264500;
CC       Q15262:PTPRK; NbExp=1; IntAct=EBI-1039152, EBI-474052;
CC       Q16827:PTPRO; NbExp=1; IntAct=EBI-1039152, EBI-723739;
CC       P63104:YWHAZ; NbExp=1; IntAct=EBI-1039152, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P08581-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08581-2; Sequence=VSP_005005;
CC         Note=No experimental confirmation available;
CC   -!- DOMAIN: The kinase domain is involved in SPSB1 binding.
CC   -!- DISEASE: Note=Activation of MET after rearrangement with the TPR
CC       gene produces an oncogenic protein.
CC   -!- DISEASE: Note=Defects in MET may be associated with gastric
CC       cancer.
CC   -!- DISEASE: Defects in MET are a cause of hepatocellular carcinoma
CC       (HCC) [MIM:114550].
CC   -!- DISEASE: Defects in MET are a cause of hereditary papillary renal
CC       carcinoma (HPRC) [MIM:605074]; also known as papillary renal cell
CC       carcinoma 2 (RCCP2). HPRC is a form of inherited kidney cancer
CC       characterized by a predisposition to develop multiple, bilateral
CC       papillary renal tumors. The pattern of inheritance is consistent
CC       with autosomal dominant transmission with reduced penetrance.
CC   -!- DISEASE: Note=A common allele in the promoter region of the MET
CC       shows genetic association with susceptibility to autism in some
CC       families. Functional assays indicate a decrease in MET promoter
CC       activity and altered binding of specific transcription factor
CC       complexes.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family.
CC   -!- SIMILARITY: Contains 3 IPT/TIG domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 Sema domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/METID131.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/MET";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=C-MET entry;
CC       URL="http://en.wikipedia.org/wiki/C-MET";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J02958; AAA59591.1; -; mRNA.
DR   EMBL; X54559; CAB56793.1; -; mRNA.
DR   EMBL; AC002080; AAB54047.1; -; Genomic_DNA.
DR   EMBL; AC002543; AAC60383.1; -; Genomic_DNA.
DR   EMBL; AC004416; AAF66137.2; -; Genomic_DNA.
DR   EMBL; U08818; AAB60323.1; ALT_SEQ; mRNA.
DR   EMBL; M35074; AAA59590.1; -; mRNA.
DR   IPI; IPI00029273; -.
DR   IPI; IPI00294528; -.
DR   PIR; A40175; TVHUME.
DR   RefSeq; NP_000236.2; -.
DR   RefSeq; NP_001120972.1; -.
DR   UniGene; Hs.132966; -.
DR   PDB; 1FYR; X-ray; 2.40 A; I/J/K/L=1356-1359.
DR   PDB; 1R0P; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 1R1W; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 1SHY; X-ray; 3.22 A; B=25-567.
DR   PDB; 1SSL; NMR; -; A=519-562.
DR   PDB; 1UX3; Model; -; A=25-656.
DR   PDB; 2G15; X-ray; 2.15 A; A=1038-1346.
DR   PDB; 2RFN; X-ray; 2.50 A; A/B=1048-1351.
DR   PDB; 2RFS; X-ray; 2.20 A; A=1048-1351.
DR   PDB; 2UZX; X-ray; 2.80 A; B/D=25-740.
DR   PDB; 2UZY; X-ray; 4.00 A; B/D=25-740.
DR   PDB; 2WD1; X-ray; 2.00 A; A=1055-1346.
DR   PDB; 2WGJ; X-ray; 2.00 A; A=1051-1348.
DR   PDB; 2WKM; X-ray; 2.20 A; A=1051-1348.
DR   PDB; 3A4P; X-ray; 2.54 A; A=1049-1360.
DR   PDB; 3BUX; X-ray; 1.35 A; A/C=997-1009.
DR   PDB; 3CE3; X-ray; 2.40 A; A=1049-1360.
DR   PDB; 3CTH; X-ray; 2.30 A; A=1049-1360.
DR   PDB; 3CTJ; X-ray; 2.50 A; A=1049-1360.
DR   PDB; 3DKC; X-ray; 1.52 A; A=1049-1360.
DR   PDB; 3DKF; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 3DKG; X-ray; 1.91 A; A=1049-1360.
DR   PDB; 3EFJ; X-ray; 2.60 A; A/B=1048-1351.
DR   PDB; 3EFK; X-ray; 2.20 A; A/B=1048-1351.
DR   PDB; 3F66; X-ray; 1.40 A; A/B=1052-1349.
DR   PDB; 3F82; X-ray; 2.50 A; A=1049-1360.
DR   PDB; 3I5N; X-ray; 2.00 A; A=1048-1351.
DR   PDB; 3L8V; X-ray; 2.40 A; A=1049-1360.
DR   PDB; 3LQ8; X-ray; 2.02 A; A=1051-1348.
DR   PDBsum; 1FYR; -.
DR   PDBsum; 1R0P; -.
DR   PDBsum; 1R1W; -.
DR   PDBsum; 1SHY; -.
DR   PDBsum; 1SSL; -.
DR   PDBsum; 1UX3; -.
DR   PDBsum; 2G15; -.
DR   PDBsum; 2RFN; -.
DR   PDBsum; 2RFS; -.
DR   PDBsum; 2UZX; -.
DR   PDBsum; 2UZY; -.
DR   PDBsum; 2WD1; -.
DR   PDBsum; 2WGJ; -.
DR   PDBsum; 2WKM; -.
DR   PDBsum; 3A4P; -.
DR   PDBsum; 3BUX; -.
DR   PDBsum; 3CE3; -.
DR   PDBsum; 3CTH; -.
DR   PDBsum; 3CTJ; -.
DR   PDBsum; 3DKC; -.
DR   PDBsum; 3DKF; -.
DR   PDBsum; 3DKG; -.
DR   PDBsum; 3EFJ; -.
DR   PDBsum; 3EFK; -.
DR   PDBsum; 3F66; -.
DR   PDBsum; 3F82; -.
DR   PDBsum; 3I5N; -.
DR   PDBsum; 3L8V; -.
DR   PDBsum; 3LQ8; -.
DR   ProteinModelPortal; P08581; -.
DR   SMR; P08581; 42-741.
DR   DisProt; DP00317; -.
DR   DIP; DIP-6023N; -.
DR   IntAct; P08581; 25.
DR   MINT; MINT-137376; -.
DR   STRING; P08581; -.
DR   PhosphoSite; P08581; -.
DR   OGP; P08581; -.
DR   PRIDE; P08581; -.
DR   Ensembl; ENST00000397752; ENSP00000380860; ENSG00000105976.
DR   GeneID; 4233; -.
DR   KEGG; hsa:4233; -.
DR   UCSC; uc010lkh.1; human.
DR   CTD; 4233; -.
DR   GeneCards; GC07P116312; -.
DR   HGNC; HGNC:7029; MET.
DR   HPA; CAB005282; -.
DR   HPA; CAB018577; -.
DR   MIM; 114550; phenotype.
DR   MIM; 164860; gene.
DR   MIM; 605074; phenotype.
DR   Orphanet; 106; Autism.
DR   Orphanet; 47044; Familial papillary renal cell carcinoma.
DR   Orphanet; 33402; Hepatocellular carcinoma, childhood-onset.
DR   PharmGKB; PA24993; -.
DR   HOVERGEN; HBG006348; -.
DR   OMA; HTPHLDR; -.
DR   OrthoDB; EOG9NZXD4; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; a6b1_a6b4_integrin_pathway; a6b1 and a6b4 Integrin signaling.
DR   Pathway_Interaction_DB; arf6cyclingpathway; Arf6 signaling events.
DR   Pathway_Interaction_DB; faspathway; FAS signaling pathway (CD95).
DR   Pathway_Interaction_DB; fgf_pathway; FGF signaling pathway.
DR   Pathway_Interaction_DB; met_pathway; Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met).
DR   Pathway_Interaction_DB; syndecan_1_pathway; Syndecan-1-mediated signaling events.
DR   Reactome; REACT_18266; Axon guidance.
DR   NextBio; 16689; -.
DR   ArrayExpress; P08581; -.
DR   Bgee; P08581; -.
DR   CleanEx; HS_MET; -.
DR   Genevestigator; P08581; -.
DR   GermOnline; ENSG00000105976; Homo sapiens.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:MGI.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005008; F:hepatocyte growth factor receptor activity; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007275; P:multicellular organismal development; IEA:InterPro.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT_TIG_rcpt.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR003659; Plexin-like.
DR   InterPro; IPR016201; Plexin-like_fold.
DR   InterPro; IPR002165; Plexin_repeat.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001627; Semaphorin/CD100_Ag.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020707; Tyr_kinase_hepatocyte_GF_rcpt.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR016244; Tyr_prot_kinase_HGF/MSP_rcpt.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 3.
DR   Gene3D; G3DSA:2.130.10.10; WD40/YVTN_repeat-like; 1.
DR   PANTHER; PTHR23256:SF169; Tyr_kinase_hepatocyte_GF_rcpt; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01437; PSI; 1.
DR   Pfam; PF01403; Sema; 1.
DR   Pfam; PF01833; TIG; 3.
DR   PIRSF; PIRSF000617; TyrPK_HGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00429; IPT; 4.
DR   SMART; SM00423; PSI; 1.
DR   SMART; SM00630; Sema; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF81296; Ig_E-set; 3.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF103575; Plexin-like_fold; 1.
DR   SUPFAM; SSF101912; Sema; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS51004; SEMA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Chromosomal rearrangement; Complete proteome; Disease mutation;
KW   Disulfide bond; Glycoprotein; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Receptor; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     24       Potential.
FT   CHAIN        25   1390       Hepatocyte growth factor receptor.
FT                                /FTId=PRO_0000024440.
FT   TOPO_DOM     25    932       Extracellular (Potential).
FT   TRANSMEM    933    955       Helical; (Potential).
FT   TOPO_DOM    956   1390       Cytoplasmic (Potential).
FT   DOMAIN       27    515       Sema.
FT   DOMAIN      563    655       IPT/TIG 1.
FT   DOMAIN      657    739       IPT/TIG 2.
FT   DOMAIN      742    836       IPT/TIG 3.
FT   DOMAIN     1078   1345       Protein kinase.
FT   NP_BIND    1084   1092       ATP (By similarity).
FT   REGION     1212   1390       Interaction with RANBP9.
FT   REGION     1320   1359       Interaction with MUC20.
FT   ACT_SITE   1204   1204       Proton acceptor (By similarity).
FT   BINDING    1110   1110       ATP.
FT   SITE        307    308       Cleavage (Potential).
FT   SITE       1009   1010       Breakpoint for translocation to form TPR-
FT                                MET oncogene.
FT   MOD_RES     966    966       Phosphoserine.
FT   MOD_RES     977    977       Phosphothreonine.
FT   MOD_RES     988    988       Phosphoserine.
FT   MOD_RES     990    990       Phosphoserine.
FT   MOD_RES     997    997       Phosphoserine.
FT   MOD_RES    1000   1000       Phosphoserine.
FT   MOD_RES    1003   1003       Phosphotyrosine.
FT   MOD_RES    1230   1230       Phosphotyrosine.
FT   MOD_RES    1234   1234       Phosphotyrosine.
FT   MOD_RES    1235   1235       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1289   1289       Phosphothreonine.
FT   MOD_RES    1356   1356       Phosphotyrosine.
FT   CARBOHYD     45     45       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    106    106       N-linked (GlcNAc...).
FT   CARBOHYD    149    149       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    202    202       N-linked (GlcNAc...).
FT   CARBOHYD    399    399       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    405    405       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    607    607       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    635    635       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    785    785       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    879    879       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    930    930       N-linked (GlcNAc...) (Potential).
FT   VAR_SEQ     755    755       S -> STWWKEPLNIVSFLFCFAS (in isoform 2).
FT                                /FTId=VSP_005005.
FT   VARIANT     143    143       R -> Q (in dbSNP:rs35469582).
FT                                /FTId=VAR_041738.
FT   VARIANT     156    156       S -> L (in dbSNP:rs56311081).
FT                                /FTId=VAR_041739.
FT   VARIANT     168    168       E -> D (in dbSNP:rs55985569).
FT                                /FTId=VAR_041740.
FT   VARIANT     238    238       L -> S (in dbSNP:rs34349517).
FT                                /FTId=VAR_032478.
FT   VARIANT     316    316       I -> M (in dbSNP:rs35225896).
FT                                /FTId=VAR_032479.
FT   VARIANT     320    320       A -> V (in dbSNP:rs35776110).
FT                                /FTId=VAR_006285.
FT   VARIANT     375    375       N -> S (in dbSNP:rs33917957).
FT                                /FTId=VAR_032480.
FT   VARIANT     773    773       P -> L (in gastric cancer).
FT                                /FTId=VAR_032481.
FT   VARIANT     970    970       R -> C (in dbSNP:rs34589476).
FT                                /FTId=VAR_032482.
FT   VARIANT     991    991       P -> S (in gastric cancer; prolonged
FT                                tyrosine phosphorylation in response to
FT                                HGF/SF; transforming activity in athymic
FT                                nude mice).
FT                                /FTId=VAR_032483.
FT   VARIANT     992    992       T -> I (in dbSNP:rs56391007).
FT                                /FTId=VAR_032484.
FT   VARIANT    1092   1092       V -> I (in HPRC; constitutive
FT                                autophosphorylation).
FT                                /FTId=VAR_032485.
FT   VARIANT    1094   1094       H -> L (in HPRC; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines).
FT                                /FTId=VAR_032486.
FT   VARIANT    1094   1094       H -> R (in HPRC; causes malignant
FT                                transformation in cell lines).
FT                                /FTId=VAR_032487.
FT   VARIANT    1094   1094       H -> Y (in HPRC; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines).
FT                                /FTId=VAR_032488.
FT   VARIANT    1106   1106       H -> D (in HPRC; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines).
FT                                /FTId=VAR_032489.
FT   VARIANT    1131   1131       M -> T (in HPRC; germline mutation).
FT                                /FTId=VAR_006286.
FT   VARIANT    1173   1173       T -> I (in HCC).
FT                                /FTId=VAR_032490.
FT   VARIANT    1188   1188       V -> L (in HPRC; germline mutation).
FT                                /FTId=VAR_006287.
FT   VARIANT    1195   1195       L -> V (in HPRC; somatic mutation).
FT                                /FTId=VAR_006288.
FT   VARIANT    1220   1220       V -> I (in HPRC; germline mutation).
FT                                /FTId=VAR_006289.
FT   VARIANT    1228   1228       D -> H (in HPRC; somatic mutation).
FT                                /FTId=VAR_006291.
FT   VARIANT    1228   1228       D -> N (in HPRC; germline mutation).
FT                                /FTId=VAR_006290.
FT   VARIANT    1230   1230       Y -> C (in HPRC; germline mutation).
FT                                /FTId=VAR_006292.
FT   VARIANT    1230   1230       Y -> D (in HPRC; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines).
FT                                /FTId=VAR_032491.
FT   VARIANT    1230   1230       Y -> H (in HPRC; somatic mutation).
FT                                /FTId=VAR_006293.
FT   VARIANT    1244   1244       K -> R (in HCC).
FT                                /FTId=VAR_032492.
FT   VARIANT    1250   1250       M -> I (in HCC).
FT                                /FTId=VAR_032493.
FT   VARIANT    1250   1250       M -> T (in HPRC; somatic mutation).
FT                                /FTId=VAR_006294.
FT   CONFLICT   1191   1191       G -> A (in Ref. 1; AAA59591).
FT   CONFLICT   1272   1272       L -> V (in Ref. 1; AAA59591, 2; CAB56793
FT                                and 6; AAA59590).
FT   STRAND       45     47
FT   STRAND       52     58
FT   STRAND       61     66
FT   STRAND       69     74
FT   TURN         75     77
FT   STRAND       80     85
FT   STRAND       89     91
FT   STRAND       93     95
FT   STRAND       97     99
FT   STRAND      102    104
FT   STRAND      111    113
FT   STRAND      117    123
FT   STRAND      125    145
FT   STRAND      154    160
FT   STRAND      182    189
FT   STRAND      192    199
FT   STRAND      213    219
FT   HELIX       231    233
FT   HELIX       241    244
FT   STRAND      248    255
FT   STRAND      258    264
FT   STRAND      276    282
FT   STRAND      292    299
FT   STRAND      319    323
FT   HELIX       327    332
FT   STRAND      341    349
FT   STRAND      353    366
FT   HELIX       367    375
FT   TURN        387    389
FT   STRAND      392    394
FT   TURN        395    398
FT   STRAND      418    422
FT   STRAND      424    427
FT   TURN        431    436
FT   STRAND      439    447
FT   STRAND      450    457
FT   STRAND      460    466
FT   STRAND      469    471
FT   STRAND      486    495
FT   TURN        496    498
FT   STRAND      499    506
FT   STRAND      509    516
FT   HELIX       517    520
FT   HELIX       526    530
FT   HELIX       534    536
FT   STRAND      539    541
FT   STRAND      544    546
FT   HELIX       548    550
FT   HELIX      1055   1057
FT   HELIX      1060   1066
FT   HELIX      1067   1069
FT   HELIX      1073   1075
FT   STRAND     1076   1087
FT   STRAND     1090   1097
FT   STRAND     1105   1112
FT   HELIX      1118   1132
FT   STRAND     1144   1148
FT   TURN       1149   1151
FT   STRAND     1152   1158
FT   HELIX      1165   1170
FT   HELIX      1178   1197
FT   HELIX      1207   1209
FT   STRAND     1210   1212
FT   STRAND     1218   1220
FT   HELIX      1224   1226
FT   TURN       1229   1233
FT   HELIX      1247   1249
FT   HELIX      1252   1257
FT   HELIX      1262   1277
FT   HELIX      1293   1297
FT   HELIX      1310   1319
FT   HELIX      1324   1326
FT   HELIX      1330   1342
FT   TURN       1354   1358
SQ   SEQUENCE   1390 AA;  155541 MW;  9CF896D1273905C3 CRC64;
     MKAPAVLAPG ILVLLFTLVQ RSNGECKEAL AKSEMNVNMK YQLPNFTAET PIQNVILHEH
     HIFLGATNYI YVLNEEDLQK VAEYKTGPVL EHPDCFPCQD CSSKANLSGG VWKDNINMAL
     VVDTYYDDQL ISCGSVNRGT CQRHVFPHNH TADIQSEVHC IFSPQIEEPS QCPDCVVSAL
     GAKVLSSVKD RFINFFVGNT INSSYFPDHP LHSISVRRLK ETKDGFMFLT DQSYIDVLPE
     FRDSYPIKYV HAFESNNFIY FLTVQRETLD AQTFHTRIIR FCSINSGLHS YMEMPLECIL
     TEKRKKRSTK KEVFNILQAA YVSKPGAQLA RQIGASLNDD ILFGVFAQSK PDSAEPMDRS
     AMCAFPIKYV NDFFNKIVNK NNVRCLQHFY GPNHEHCFNR TLLRNSSGCE ARRDEYRTEF
     TTALQRVDLF MGQFSEVLLT SISTFIKGDL TIANLGTSEG RFMQVVVSRS GPSTPHVNFL
     LDSHPVSPEV IVEHTLNQNG YTLVITGKKI TKIPLNGLGC RHFQSCSQCL SAPPFVQCGW
     CHDKCVRSEE CLSGTWTQQI CLPAIYKVFP NSAPLEGGTR LTICGWDFGF RRNNKFDLKK
     TRVLLGNESC TLTLSESTMN TLKCTVGPAM NKHFNMSIII SNGHGTTQYS TFSYVDPVIT
     SISPKYGPMA GGTLLTLTGN YLNSGNSRHI SIGGKTCTLK SVSNSILECY TPAQTISTEF
     AVKLKIDLAN RETSIFSYRE DPIVYEIHPT KSFISGGSTI TGVGKNLNSV SVPRMVINVH
     EAGRNFTVAC QHRSNSEIIC CTTPSLQQLN LQLPLKTKAF FMLDGILSKY FDLIYVHNPV
     FKPFEKPVMI SMGNENVLEI KGNDIDPEAV KGEVLKVGNK SCENIHLHSE AVLCTVPNDL
     LKLNSELNIE WKQAISSTVL GKVIVQPDQN FTGLIAGVVS ISTALLLLLG FFLWLKKRKQ
     IKDLGSELVR YDARVHTPHL DRLVSARSVS PTTEMVSNES VDYRATFPED QFPNSSQNGS
     CRQVQYPLTD MSPILTSGDS DISSPLLQNT VHIDLSALNP ELVQAVQHVV IGPSSLIVHF
     NEVIGRGHFG CVYHGTLLDN DGKKIHCAVK SLNRITDIGE VSQFLTEGII MKDFSHPNVL
     SLLGICLRSE GSPLVVLPYM KHGDLRNFIR NETHNPTVKD LIGFGLQVAK GMKYLASKKF
     VHRDLAARNC MLDEKFTVKV ADFGLARDMY DKEYYSVHNK TGAKLPVKWM ALESLQTQKF
     TTKSDVWSFG VLLWELMTRG APPYPDVNTF DITVYLLQGR RLLQPEYCPD PLYEVMLKCW
     HPKAEMRPSF SELVSRISAI FSTFIGEHYV HVNATYVNVK CVAPYPSLLS SEDNADDEVD
     TRPASFWETS
//
